Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers - Wikidata - wikimedia - TriplyDB

Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers

Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers

http://www.wikidata.org/entity/Q28069910

about

Impact of palbociclib combinations on treatment of advanced estrogen receptor-positive/human epidermal growth factor 2-negative breast cancer Antizyme inhibitor 1: a potential carcinogenic molecule Breast Cancer Immunotherapy: Facts and Hopes.Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of action, Clinical Activity, and Safety Profiles.CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update.Metastatic breast cancer: The Odyssey of personalization.Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients.Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016).Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician.CDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure.A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.Predicting Triple-Negative Breast Cancer Subtype Using Multiple Single Nucleotide Polymorphisms for Breast Cancer Risk and Several Variable Selection Methods.Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity.Unintended target effect of anti-BCL-2 DNAi.Abemaciclib: First Global Approval.Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.Therapeutic Challenge With a CDK 4/6 Inhibitor Induces an RB-dependent SMAC Mediated Apoptotic Response in Non-Small Cell Lung Cancer.Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions.Protein Kinase Targets in Breast Cancer.Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance.Ribociclib for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer.Targeting the cyclin dependent kinase and retinoblastoma axis overcomes standard of care resistance in BRAF V600E -mutant melanoma.20(S)-Protopanaxadiol-Induced Apoptosis in MCF-7 Breast Cancer Cell Line through the Inhibition of PI3K/AKT/mTOR Signaling Pathway.Specific CDK4/6 inhibition in breast cancer: a systematic review of current clinical evidence.The role of abemaciclib in treatment of advanced breast cancer.Hormone receptor-positive, HER2-negative metastatic breast cancer: redrawing the lines.ERα-mediated cell cycle progression is an important requisite for CDK4/6 inhibitor response in HR+ breast cancer.Multiregion Comprehensive Genomic Profiling of a Gastric Mixed Neuroendocrine-Nonneuroendocrine Neoplasm with Trilineage Differentiation.Profile of abemaciclib and its potential in the treatment of breast cancer CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis Targeting the cell cycle in breast cancer: towards the next phase LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERα pathway Centrosome aberrations and chromosome instability contribute to tumorigenesis and intra-tumor heterogeneity

P2860

Q28072793-F1AD79D5-5EF6-485A-946E-F1E3B2626BE6 Q28074076-F471C87F-0EB8-461C-84E3-76E6D13B85A4 Q38628198-EDB2F091-CE61-46F5-8F7E-75A10B4A0443 Q38832541-C8042F03-E4BA-47E4-B187-3F3355471003 Q38866877-983B4DF7-6F8A-4380-822C-98FFE74C99F7 Q38870640-49FAEC45-354D-4583-BAE8-8668FB5A8172 Q38901163-6B46E410-F904-4208-BBDB-8A5A2F394A0D Q38933237-30F62727-59F9-47E3-9A40-F4DBAD4EA7A3 Q38949247-723194F0-D08A-488F-B383-3125E29D2690 Q39233197-C25FBF55-29C4-4187-946B-3434AD1C8916 Q39289608-9C3F350C-3334-49DC-8D36-D3A67CE0829E Q39402106-EA3D657A-D706-4929-B25B-CEE60AAE51F0 Q41011976-56540172-1E2A-40FE-B6AB-B38FAEEBB2CC Q42070222-B3474C96-65B7-4B03-A964-390807A9A325 Q42286844-76CE0F8E-53BF-45E6-BA96-51CC83099471 Q43280771-7BA060BC-D9B5-408A-9561-BA2CA43F6F8C Q45348344-7E9A7A6C-11C3-4A50-AA40-4EDBC816D561 Q47223157-B2E8736E-6760-43FB-9D3A-FA2460A0180B Q47316489-A84B177A-9BEB-49CD-9BE7-742D1197DA85 Q47351355-9DF9D713-F85F-414D-A79B-27282F8E9400 Q47551153-F0166D54-31DD-45FA-8BFD-E32EB090D6B7 Q47850321-002CABEA-7181-4F07-8548-325348164D1B Q48512373-313EA621-49BE-455C-95CF-AD1F66D83F16 Q52655061-2F165067-2708-46DE-BCAA-432B11C0B983 Q52721972-ED054F66-56F6-4741-822F-A5D35AD9CB32 Q54969586-C2256E59-CB6F-47F0-97D3-27E4545D6855 Q55124984-115C04E4-218C-463A-9DE8-FCA1E595CF0B Q55423791-4BC25FC8-1E9B-4D45-A699-4F0B020B7841 Q55426345-518097A6-129A-43B0-8629-46CC8F344C05 Q55465621-0A75A8F0-65C1-40FA-A75C-5C122986C741 Q57107448-3A731174-74AC-480B-87CC-368DA604B3F7 Q57107726-F67DCAE4-2E44-4EA9-BFF1-E653B98CB0C3 Q57112840-A0600222-BACE-4A88-8FBC-669B30EBB5AD Q57115037-285B3384-B6CC-4D47-B101-E93B7B3C9E14 Q57291547-FB72B896-5CD7-4D84-A5AA-253E48245687 Q58132668-D17BF9CD-BE9F-4AD8-8227-25E6252BD99C

P2860

Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers

http://www.wikidata.org/entity/Q28069910

description

2016 nî lūn-bûn

@nan

2016 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Targeting the cyclin-dependent ...... ceptor-positive breast cancers

@ast

Targeting the cyclin-dependent ...... ceptor-positive breast cancers

@en

Targeting the cyclin-dependent ...... ceptor-positive breast cancers

@nl

type

label

Targeting the cyclin-dependent ...... ceptor-positive breast cancers

@ast

Targeting the cyclin-dependent ...... ceptor-positive breast cancers

@en

Targeting the cyclin-dependent ...... ceptor-positive breast cancers

@nl

prefLabel

Targeting the cyclin-dependent ...... ceptor-positive breast cancers

@ast

Targeting the cyclin-dependent ...... ceptor-positive breast cancers

@en

Targeting the cyclin-dependent ...... ceptor-positive breast cancers

@nl

P1433

Q28069910-DD1D8E51-0DAC-4F0B-8B30-5C977C90E41A

P1476

Q28069910-F5B86A18-83DC-4185-B25C-9F3C9BA8FBE0

P2093

Q28069910-8F894105-86AA-4DEA-BC77-B644F940C497

Q28069910-B9D91FB4-167A-411D-B348-79249F25E42C

Q28069910-D176C1A5-D44A-4B78-BF8E-EC1946B45C45

P275

Q28069910-ED4C2E90-D6B3-4A23-8005-6D3E16D664DE

P2860

Q28069910-033648B1-832B-4669-89D9-6F739A28D9F9

Q28069910-047E54B1-1E8A-4021-B98E-1CDBF3248A41

Q28069910-0537A36E-FCF4-4395-BE7B-B0F74B436D30

Q28069910-09E6FF9D-0F67-44D3-B566-551D248E30A8

Q28069910-0BC11D9E-FDE2-45CA-AEAD-F9F330FF704B

Q28069910-0D111776-D2B9-4DD4-9E7F-B7043EDF1272

Q28069910-0E0CAC90-63C3-4D8D-976D-C2B2D40073FE

Q28069910-1165B3B3-28E0-4567-98FF-2D4EE0010A8E

Q28069910-1ABE45D4-369F-4898-AC7F-A89565C6664E

Q28069910-27222CFE-C6CF-4D82-A6E2-B24D8D6CC1C6

P2888

Q28069910-1A5857B2-ECBE-4007-8DA9-B0DC6781DE0B

P304

Q28069910-BCC48612-D5BE-4CAD-8F3B-F5C1A87F53F6

P31

Q28069910-3B613D7B-71C2-4BB8-9D11-BC64DCEDEF1F

Q28069910-89FEBE8D-406E-46A2-8374-5E331CACB095

P3181

Q28069910-6D627805-1D2B-49C3-86B6-2606C1CB59DD

P356

Q28069910-75D6719B-D3BF-4A8D-B71A-0B28260D0FD0

P407

Q28069910-BE165E0D-C8A2-4DD2-817F-BC2B985F44A3

P433

Q28069910-6AF51B6B-4B06-4DFF-A19D-A8BFD5F78A98

P478

Q28069910-DCE1CF1E-1327-401E-9B5A-EA066AB18387

P5008

Q28069910-B61E974F-FEB3-438C-BEEE-1F49FF9104DD

P577

Q28069910-635773D9-ECAD-47AF-AF51-2A3C24FE3ACB

P5875

Q28069910-33FAFF2B-D956-4EF5-9966-B88F83D19891

P6179

Q28069910-59B01055-796F-4E0A-B7D4-3C4D0CE6D93C

P698

Q28069910-D0156CB3-DCD2-4026-B41D-46D7572BA600

P921

Q28069910-1064AC6B-F304-47CF-821D-25C90459514A

Q28069910-280CD0AE-5920-4875-AE8B-B1D91663E55B

Q28069910-35B25038-69B2-4988-BD13-9A1141742790

Q28069910-7D3F1D90-9519-4947-AC4B-40C55F5D760D

Q28069910-BEAA4977-72F5-4A81-843D-9A8CE6DB7446

Q28069910-DBFC99DB-9E45-4457-A06F-9E63D39521AB

P932

Q28069910-CB377B37-7685-4257-9F78-5C4B379BA90C

P3181

P356

S13058-015-0661-5

P1433

Breast Cancer Research

P1476

Targeting the cyclin-dependent ...... ceptor-positive breast cancers

@en

P2093

Alexey Aleshin

http://www.w3.org/2001/XMLSchema#string

Dennis J. Slamon

http://www.w3.org/2001/XMLSchema#string

Richard S. Finn

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

Global cancer statistics

Hallmarks of Cancer: The Next Generation

A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells

Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase

Cell cycle, CDKs and cancer: a changing paradigm

Distinct interactions select and maintain a specific cell fate.

Alternative cyclin D1 splice forms differentially regulate the DNA damage response

Comprehensive molecular portraits of human breast tumours

Genetic control of the cell-division cycle in yeast. I. Detection of mutants

P2888

s13058-015-0661-5

P304

17

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3038138

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/S13058-015-0661-5

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2016-02-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

293636911

http://www.w3.org/2001/XMLSchema#string

P6179

1005578750

http://www.w3.org/2001/XMLSchema#string

P698

26857361

http://www.w3.org/2001/XMLSchema#string

P921

heterocyclic compound

breast neoplasm

cell cycle proteins

P932

4746893

http://www.w3.org/2001/XMLSchema#string